GSK Doubles COiMMUNITY Grant Funding, Launches Patient Resources, as Adult Vaccination Rates Begin to Show Promising Rise
-
Under its COiMMUNITY Initiative, GSK is committing up to
$2 million in 2024 to support adult immunization and health equity - GSK launches new patient-centered resources to facilitate provider-patient vaccination conversations and recommendations
- New Q3 2023 Vaccine Track data show potential return of adult immunization rates to pre-pandemic levels, largely driven by an increase in Medicare and Medicaid claims
Increased Funding
In 2024, GSK is giving up to
Eligible organizations interested in applying for 2024 grant funding should respond to the Request for Proposals on gskfunding.com and address their response to the COiMMUNITY Initiative. GSK will review and approve grant proposals on a rolling basis according to set principles and criteria until mid-November of 2024.
New Resources
A recent GSK survey found that many adults ages 50-79 are unfamiliar with the vaccines recommended for them, and physicians indicate that most adults are unlikely to receive many of the vaccines they recommend. GSK is equipping healthcare providers and their patients with simple tools to spur action and follow through on vaccination. These two new resources include: a patient vaccine log and EasyVax™, a mobile vaccine scheduler. The vaccine log helps healthcare providers and patients track year-round vaccinations and identify potential immunization gaps. EasyVax helps providers streamline the pharmacy vaccine referral process, empowering patients to quickly locate and schedule retail vaccine appointments from anywhere, including a provider’s office at the point of recommendation.
GSK will also continue to share new resources, tools and best practices in adult vaccine confidence and delivery via interactive webinars.
New Data
According to Vaccine Track data published today, in Q1-Q3 2023, average adult monthly non-flu vaccination rates are 1% higher than the same time period in 2019. This is the first-time data show average adult vaccination rates are higher than pre-pandemic levels. The data, which captures claims through Q3 2023, suggest that an uptick in Medicare and Medicaid vaccination claims drove the increase, as commercial claims were 4% lower in Q1-Q3 2023 compared to the same time period in 2019.
While it is too early to assess how much of the increase in average monthly claims is a result of the Inflation Reduction Act (IRA) versus seasonality or other factors, the IRA’s elimination of adult vaccination cost-sharing under Medicare – extended to Medicaid-enrolled adults in
About Vaccine Track
Vaccine Track is a comprehensive platform developed by GSK, in collaboration with
Vaccine Track is open to public and private stakeholders, welcoming the opportunity to potentially integrate and host additional data and viewpoints on adult vaccination trends. Data integration is subject to a Data Licensing Agreement.
About GSK
GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com.
Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D “Risk factors” in the company's Annual Report on Form 20-F for 2022, and Q4 Results for 2023.
Registered in
No. 3888792
Registered Office:
Brentford,
TW8 9GS
View source version on businesswire.com: https://www.businesswire.com/news/home/20240306698092/en/
GSK inquiries
Media:
Investor Relations:
Source: